Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction

Lucie M Turcotte; Ashley Yingst; Michael R Verneris

doi:10.1016/j.bbmt.2016.03.016

Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction

Lucie M Turcotte, Ashley Yingst, Michael R Verneris

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

Original language	English (US)
Pages (from-to)	1159-1166
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	22
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2016.03.016
State	Published - Jul 1 2016

Bibliographical note

Funding Information:
This work was supported in part by Institutional Research Grant number 124166-IRG-58-001-55-IRG22 from the American Cancer Society (L.M.T.), Hyundai Hope on Wheels Young Investigator Clinical Grant (L.M.T.), the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (L.M.T,), and 5R01AI100879-03 (M.R.V.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2016 American Society for Blood and Marrow Transplantation.

Keywords

Hematopoietic cell transplantation
Late effects
Metabolic syndrome
Survivor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.bbmt.2016.03.016

OpenUrl availability

Full text

Cite this

@article{aec851387c7145cf8e9103db17f01b49,

title = "Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction",

abstract = "Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.",

keywords = "Hematopoietic cell transplantation, Late effects, Metabolic syndrome, Survivor",

author = "Turcotte, {Lucie M} and Ashley Yingst and Verneris, {Michael R}",

note = "Funding Information: This work was supported in part by Institutional Research Grant number 124166-IRG-58-001-55-IRG22 from the American Cancer Society (L.M.T.), Hyundai Hope on Wheels Young Investigator Clinical Grant (L.M.T.), the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (L.M.T,), and 5R01AI100879-03 (M.R.V.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2016 American Society for Blood and Marrow Transplantation.",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.bbmt.2016.03.016",

language = "English (US)",

volume = "22",

pages = "1159--1166",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Metabolic Syndrome after Hematopoietic Cell Transplantation

T2 - At the Intersection of Treatment Toxicity and Immune Dysfunction

AU - Turcotte, Lucie M

AU - Yingst, Ashley

AU - Verneris, Michael R

N1 - Funding Information: This work was supported in part by Institutional Research Grant number 124166-IRG-58-001-55-IRG22 from the American Cancer Society (L.M.T.), Hyundai Hope on Wheels Young Investigator Clinical Grant (L.M.T.), the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (L.M.T,), and 5R01AI100879-03 (M.R.V.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2016 American Society for Blood and Marrow Transplantation.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

AB - Hematopoietic cell transplantation (HCT) survivors face a multitude of short- and long-term health complications in the years after treatment. One important health complication that is associated with significant morbidity is metabolic syndrome (MetSyn). This constellation of findings, which includes obesity, glucose and lipid dysmetabolism, and hypertension, places affected individuals at increased risk for type 2 diabetes mellitus, cardiovascular complications, and stroke. Previous studies have linked MetSyn in HCT survivors to prior treatment; however, few studies have addressed the potential roles of systemic inflammation and immune system dysfunction after HCT. Within this review, we address the recent advances in the understanding of adipose tissue biology, immune, and inflammatory mechanisms involved in MetSyn in non-HCT patients, and lastly, we discuss potential novel mechanisms that may play a role in MetSyn development after HCT, such as hematopoietic stem cell source, inflammatory status of the stem cell donor, and microbiome composition, all of which represent potential new directions for post-HCT MetSyn research.

KW - Hematopoietic cell transplantation

KW - Late effects

KW - Metabolic syndrome

KW - Survivor

UR - http://www.scopus.com/inward/record.url?scp=84969551370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969551370&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.03.016

DO - 10.1016/j.bbmt.2016.03.016

M3 - Review article

C2 - 27013015

AN - SCOPUS:84969551370

SN - 1083-8791

VL - 22

SP - 1159

EP - 1166

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -

Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this